<DOC>
	<DOCNO>NCT01031446</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving cisplatin paclitaxel together everolimus may kill tumor cell . PURPOSE : This phase I/II trial study side effect give cisplatin paclitaxel together everolimus see well work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Cisplatin , Paclitaxel , Everolimus Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Safety profile cisplatin , paclitaxel , everolimus ( RAD001 ) patient metastatic breast cancer . ( Phase I ) - Progression-free survival ( Phase II ) Secondary - Overall response rate - Time progression - Number patient worst-grade toxicity Tertiary - To determine p53 , p63 , p73 , phosphatase tensin homolog ( PTEN ) level immunohistochemistry ( IHC ) . - To screen exon 9 ( E542K E545K ) , exon 20 ( H1047R ) , phosphatidylinositol 3-kinase ( PI3K ) ( p110α ) mutation DNA extract paraffin block . - To correlate IHC result clinical outcome different subtypes breast cancer determine molecular classification ( basal-type v luminal A vs luminal B ) base microarrays RNA extract formalin-fixed paraffin-embedded block . - To generate microarrays RNA extract fresh-frozen core biopsy ( available ) identify pretreatment gene signature mirror establish p63 p73 gene signature predict response treatment . OUTLINE : This multicenter study . Patients receive oral everolimus daily day 1-28 cisplatin IV 1 hour paclitaxel IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Tumor tissue sample collect baseline correlative study . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive mammary carcinoma Stage IV disease Basallike disease ( triplenegative , hormonerefractory , HER2negative ) No locally recurrent breast cancer No symptomatic brain metastasis Patients history brain metastasis eligible provide clinically stable &gt; 3 week completion radiotherapy take steroid therapeutic anticonvulsant cytochrome P450 3A4 ( CYP3A4 ) modifier Patients asymptomatic brain metastasis eligible provide take prophylactic anticonvulsant CYP3A4 modifier PATIENT CHARACTERISTICS : Pre postmenopausal European Cooperative Oncology Group ( ECOG ) performance status 01 Life expectancy ≥ 6 month Absolute neutrophil count ( ANC ) ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN ( ≤ 3 time ULN presence liver metastasis ) Direct bilirubin measure patient Gilbert syndrome serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) ≤ 1.5 time ULN ( ≤ 3 time ULN presence liver metastasis ) Alkaline phosphatase ≤ 3 time ULN ( presence liver metastasis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment Able swallow retain oral medication No malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel No concurrent uncontrolled illness include , limited , follow : Ongoing active infection require parenteral antibiotic Impaired lung function ( chronic obstructive pulmonary disease lung condition require oxygen therapy ) New York Heart Association class IIIIV congestive heart failure Unstable angina pectoris , angioplasty , stenting , myocardial infarction within past 6 month Uncontrolled hypertension ( systolic BP &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg , find 2 consecutive measurement separate 1week period despite adequate medical support ) Clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ grade 3 accord NCI Common Toxicity Criteria Adverse Events v3.0 ] ) Uncontrolled diabetes ( hyperosmolar state , ketoacidosis , etc . ) Psychiatric illness social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary No symptomatic neuropathy ≥ grade 2 No invasive cancer within past 5 year except completely resect basal cell squamous cell carcinoma skin successfully treat cervical carcinoma situ No hypersensitivity paclitaxel drug use vehicle Cremophor , Chinese hamster ovary cell product , recombinant human antibodies No history hepatitis B C PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy Prior total cumulative lifetime dose doxorubicin ≤ 360 mg/m^2 epirubicin ≤ 640 mg/m^2 No 4 prior chemotherapy treatment metastatic setting ( include endocrine therapy singleagent biologic therapy ) At least 2 week since prior investigational drug At least 14 day since prior concurrent herbal dietary supplement At least 14 day since prior concurrent CYP3A4 inducer At least 7 day since prior concurrent CYP3A4 inhibitor Concurrent radiotherapy painful bone metastasis area impend bone fracture allow provide radiotherapy initiate study entry No concurrent anticancer therapy ( chemotherapy , radiotherapy , surgery , immunotherapy , hormonal therapy , biologic therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>Human epidermal growth factor ( HER2 ) -negative breast cancer</keyword>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>hormone-resistant breast cancer</keyword>
</DOC>